J Korean Ophthalmol Soc > Volume 50(2); 2009 > Article
Journal of the Korean Ophthalmological Society 2009;50(2):202-210.
DOI: https://doi.org/10.3341/jkos.2009.50.2.202    Published online February 15, 2009.
Effects and Prognostic Factors of Intravitreal Bevacizumab Injection on Choroidal Neovascularization from Age-Related Macular Degeneration.
Se Beum Oh, Won Bin Cho, Jun Woong Moon, Hyung Chan Kim
Department of Ophthalmology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. eyekim@kuh.ac.kr
나이관련 황반변성의 맥락막신생혈관에서 베바시주맙 유리체강내 주입술 효과와 예후인자
오세범ㆍ조원빈ㆍ문준웅ㆍ김형찬
Department of Ophthalmology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea
Abstract
PURPOSE
To investigate the effects and prognostic factors related to intravitreal injection of bevacizumab on patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. METHODS: The medical records of patients who received 3 consecutive intravitreal injections of bevacizumab (1.25 mg/0.05 ml, 6 weeks interval) for subfoveal choroidal neovascularization secondary to age-related macular degeneration and followed up for more than 12 months were reviewed (a total of 31 eyes; male, 20; mean age, 72.3+/-7.5 years). Baseline best corrected visual acuity, foveal thickness, and total macular volume were compared with those after 1, 4, and 12 months. The therapeutic effects were investigated with regard to factors such as age, sex, initial visual acuity, lesion size, subtypes of choroidal neovascularization, pigment epithelial detachment, submacular hemorrhage, and previous history of photodynamic therapy. RESULTS: Initial visual acuity (logMAR), foveal thickness, and total macular volume were 0.74+/-0.49, 320+/-88 microm and 9.50+/-2.99 mm3, respectively. Visual acuity improved to 0.68+/-0.61 (p=0.012), and foveal thickness and total macular volume decreased to 218+/-69 microm and 6.32+/-0.71 mm3 (p<0.001), respectively, at 12 months. Visual improvement was achieved less often in patients who were 75 years or older and who had lesions 3 disc areas or greater and relatively good initial vision at 12 months. CONCLUSIONS: Intravitreal bevacizumab injection has beneficial effects for patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration with regard to function and anatomy. However, it should be noted that visual improvement may be limited in older patients with larger lesions and good initial vision.
Key Words: Age-related macular degeneration;Choroidal neovascularization;Intravitreal bevacizumab injection


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next